Retinoids augment the bystander effect in vitro and in vivo in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy

Gene Therapy

Volumn 4, Issue 9, 1997, Pages 909-917

  Park, J Y ^a   Elshami, A A ^b   Amin, K ^b   Rizk, N ^b   Kaiser, L R ^b   Albelda, S M ^b  

^a Kyungpook National University School of Medicine   (South Korea)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bystander effect; Ganciclovir; Gap junctions; Gene therapy; HSV thymidine kinase; Retinoids

Indexed keywords

GANCICLOVIR; GAP JUNCTION PROTEIN; PRODRUG; RETINOID; THYMIDINE KINASE; VIRUS VECTOR;

ARTICLE; CELL COMMUNICATION; CELL JUNCTION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; NONHUMAN; PRIORITY JOURNAL;

EID: 0030801745     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300477     Document Type: Article

References (39)

1. Moolten FL. Drug sensitivity ('suicide') genes for selective cancer therapy. Cancer Gene Ther 1994; 1: 279-287.
2. Miller AD. Human gene therapy comes of age. Nature 1992; 357: 455-460.
3. Guzman RJ et al. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994; 91: 10732-10736.
4. Chang MW et al. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery. Mol Med 1995; 1: 172-181.
5. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297-300.
6. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988; 10: S490-S494.
7. Samejima Y, Meruelo D. 'Bystander killing' induces apoptosis and is inhibited by forskolin. Gene Therapy 1995; 2: 50-58.
8. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
9. Freeman SM et al. The bystander effect: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
10. Smythe WR et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thor Surg 1994; 57: 1395-1401.
11. Hwang HC et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 1995; 13: 7-16.
12. Smythe WR et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 1995; 222: 78-86.
13. Elshami AA et al. Treatment of malignant pleural mesothelioma in an immunocompetent rat model utilizing adenovirus-mediated gene therapy. Hum Gene Ther 1996; 7: 141-148.
14. Ezzedine ZD et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608-614.
15. Osaki T et al. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by type-specific expression of herpes simplex thymidine kinase gene. Cancer Res 1994; 53: 5258-5261.
16. Elshami AA et al. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Therapy 1996; 3: 85-92.
17. Li Bi W, Parysek LM, Warnick R, Stambrook PJ. In vivo evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
18. Fick J et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 1995; 92: 11071-11075.
19. Mesnil M et al. Bystander killing of cancer by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 1996; 93: 1831-1835.
20. Bennett MVL et al. Gap junctions: new tools, new answers, new questions. Neuron 1991; 6: 305-320.
21. Dermietzel R, Spray DC. Gap junctions in the brain: where, what type, how many and why? Trends Neurosci 1993; 16: 186-192.
22. Pelin K, Hirvonen A, Linnainmaa K. Expression of cell adhesion molecules and connexins in gap junctional intercellular communication deficient human mesothelioma tumour cell lines and communication competent primary mesothelial cells. Carcinogenesis 1994; 15: 2673-2675.
23. Zhang L, Acevedo P, Guo H, Bertram JS. Upregulation of gap junctional communication and connexin43 gene expression by carotenoids in human dermal fibroblasts but not in human keratinocytes. Mol Carcinogenesis 1995; 12: 50-58.
24. Guo H, Acevedo P, Parsa FD, Bertram JS. Gap-junctional protein connexin43 is expressed in dermis and epidermis of human skin: differential modulation by retinoids. J Invest Dermatol 1992; 99: 460-467.
25. Mehta PP, Loewenstein WR. Differential regulation of communication by retinoic acid in homologous and heterologous junctions between normal and transformed cells. J Cell Biol 1991; 113: 371-379.
26. Tomasetto C et al. Specificity of gap junction communication among human mammary cells and connexin transfectants in culture. J Cell Biol 1993; 122: 157-167.
27. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents (part I). Cancer Treat Rep 1987; 4: 391-405.
28. Blomhoff R et al. Transport and storage of vitamin A. Science 1990; 250: 399-404.
29. Napoli JL et al. Quantification of retinoic acid by gas-liquid chromatography-mass spectrometry: total versus all-trans-retinoic acid in human plasma. J Lipid Res 1985; 26: 387-392.
30. Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-864.
31. Rogers M et al. Retinoid-enhanced gap junctional communication is achieved by increased levels of connexin 43 mRNA and protein. Mol Carcinogenesis 1990; 3: 335-343.
32. Lotan R, Nicolson GL. Inhibitory effects of retinoic acid or retinyl acetate on the growth of untransformed, transformed, and tumor cells in vitro. J Natl Cancer Inst 1977; 59: 1717-1722.
33. Mehta PP, Bertram JS, Loewenstein WR. The actions of retinoids on cellular growth correlate with their actions on gap junctional communication. J Cell Biol 1989; 108: 1053-1065.
34. Smythe WR et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994; 57: 1395-1401.
35. Davis MR et al. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992; 52: 881-887.
36. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 980-990.
37. Englehardt JF et al. Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenovirus. Nat Genet 1993; 4: 27-34.
38. Smythe WR et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 1994; 54: 2055-2059.
39. Alley MC et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48: 589-601.